Emergent BioSolutions (EBS) Tops Q1 EPS by 41c; Guides Q2 Revs Lower
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.50 -1.96%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $1.53, $0.41 better than the analyst estimate of $1.12. Revenue for the quarter came in at $343 million versus the consensus estimate of $358.47 million.
GUIDANCE:
Emergent BioSolutions sees Q2 2021 revenue of $370-430 million, versus the consensus of $502.3 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- The LGL Group (LGL) Misses Q2 EPS by 8c
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
